PriceTargets.com logo

Cartesian Therapeutics - RNAC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $32.60
  • Forecasted Upside: 317.95%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.80 As of 07/31/2026 05:00 PM ET
▲ +0.07 (0.91%)

This chart shows the closing price for RNAC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cartesian Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RNAC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RNAC

Analyst Price Target is $32.60
▲ +317.95% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Cartesian Therapeutics in the last 3 months. The average price target is $32.60, with a high forecast of $44.00 and a low forecast of $16.00. The average price target represents a 317.95% upside from the last price of $7.80.

This chart shows the closing price for RNAC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 investment analysts is to moderate buy stock in Cartesian Therapeutics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/8/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/3/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/4/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
7/3/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/29/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
6/30/2026Zacks ResearchDowngradeHold ➝ Strong Sell
6/12/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
6/10/2026WedbushReiterated RatingOutperform ➝ Outperform$38.00
6/9/2026Needham & Company LLCReiterated RatingBuy ➝ Buy$40.00
6/9/2026BTIG ResearchReiterated RatingBuy ➝ Buy$44.00
5/27/2026WedbushReiterated RatingOutperform ➝ Outperform$38.00
5/26/2026Needham & Company LLCLower TargetBuy ➝ Buy$42.00 ➝ $40.00
5/12/2026HC WainwrightLower TargetBuy ➝ Buy$30.00 ➝ $25.00
5/1/2026WedbushReiterated RatingOutperform ➝ Outperform$38.00
3/27/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
3/10/2026WedbushReiterated RatingOutperform ➝ Outperform$38.00
3/9/2026BTIG ResearchReiterated RatingBuy ➝ Buy
3/9/2026Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00
3/9/2026Cantor FitzgeraldUpgradeNeutral ➝ Overweight$16.00
1/9/2026Needham & Company LLCBoost TargetBuy ➝ Buy$40.00 ➝ $42.00
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/15/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/25/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/19/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/19/2025HC WainwrightLower TargetBuy ➝ Buy$40.00 ➝ $30.00
11/14/2025BTIG ResearchBoost TargetBuy ➝ Buy$42.00 ➝ $44.00
11/13/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/9/2025WedbushInitiated CoverageOutperform$38.00
5/8/2025Needham & Company LLCLower TargetBuy ➝ Buy$41.00 ➝ $40.00
4/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
4/9/2025HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
3/14/2025HC WainwrightLower TargetBuy ➝ Buy$45.00 ➝ $40.00
3/13/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
1/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
1/27/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
1/13/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
12/19/2024BTIG ResearchInitiated CoverageBuy$42.00
12/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$41.00 ➝ $45.00
12/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
12/2/2024Cantor FitzgeraldUpgradeHold
11/25/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
11/8/2024HC WainwrightLower TargetBuy ➝ Buy$45.00 ➝ $41.00
11/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
10/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
9/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
9/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
8/12/2024HC WainwrightLower TargetBuy ➝ Buy$49.00 ➝ $45.00
8/9/2024Needham & Company LLCLower TargetBuy ➝ Buy$42.00 ➝ $41.00
8/6/2024TD CowenInitiated CoverageBuy
7/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
7/3/2024HC WainwrightLower TargetBuy ➝ Buy$54.00 ➝ $49.00
7/3/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$38.00 ➝ $43.00
7/2/2024OppenheimerDowngradeOutperform ➝ Market Perform
7/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
6/24/2024OppenheimerReiterated RatingOutperform ➝ Outperform$50.00 ➝ $50.00
6/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$54.00 ➝ $54.00
6/14/2024OppenheimerReiterated RatingOutperform ➝ Outperform$50.00 ➝ $50.00
6/4/2024OppenheimerInitiated CoverageOutperform$50.00
5/24/2024MizuhoInitiated CoverageBuy$40.00
5/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$54.00 ➝ $54.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$54.00
5/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00
4/23/2024Leerink PartnersReiterated RatingOutperform
4/23/2024HC WainwrightBoost TargetBuy ➝ Buy$2.00 ➝ $54.00
4/23/2024Leerink PartnersInitiated CoverageOutperform$39.00
4/9/2024Needham & Company LLCInitiated CoverageBuy ➝ Buy$42.00
3/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00
3/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00
(Data available from 8/2/2021 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/4/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/5/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2026

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Cartesian Therapeutics logo
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $7.80
Low: $7.31
High: $7.80

50 Day Range

MA: $8.44
Low: $5.84
High: $10.59

52 Week Range

Now: $7.80
Low: $5.60
High: $13.21

Volume

140,248 shs

Average Volume

129,981 shs

Market Capitalization

$229.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Cartesian Therapeutics?

The following equities research analysts have issued stock ratings on Cartesian Therapeutics in the last twelve months: BTIG Research, Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, Wall Street Zen, Wedbush, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for RNAC.

What is the current price target for Cartesian Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cartesian Therapeutics in the last year. Their average twelve-month price target is $32.60, suggesting a possible upside of 317.9%. BTIG Research has the highest price target set, predicting RNAC will reach $44.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $16.00 for Cartesian Therapeutics in the next year.
View the latest price targets for RNAC.

What is the current consensus analyst rating for Cartesian Therapeutics?

Cartesian Therapeutics currently has 1 sell rating, 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RNAC.

What other companies compete with Cartesian Therapeutics?

Other companies that are similar to Cartesian Therapeutics include Sana Biotechnology, Kura Oncology, Arbutus Biopharma, Theravance Biopharma and Amphastar Pharmaceuticals. Learn More about companies similar to Cartesian Therapeutics.

How do I contact Cartesian Therapeutics' investor relations team?

Cartesian Therapeutics' physical mailing address is 65 Grove Street, Watertown, MA 02472, United States. The company's listed phone number is 617-923-1400 and its investor relations email address is [email protected]. The official website for Cartesian Therapeutics is selectabio.com. Learn More about contacing Cartesian Therapeutics investor relations.